Syndax Pharmaceuticals (SNDX) Change in Accured Expenses (2015 - 2026)

Syndax Pharmaceuticals' Change in Accured Expenses history runs 12 years deep, the most recent figure standing at -$28.3 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 1019.19% year-over-year to -$28.3 million in Q1 2026; TTM through Mar 2026 was $16.4 million, a 29.87% decrease from a year earlier, with the FY2025 full-year figure at $42.2 million, up 120.32% from the prior year.
• Change in Accured Expenses declined to -$28.3 million in Q1 2026 per SNDX's latest filing, from $25.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $25.7 million in Q4 2025 and bottomed at -$28.3 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $2.4 million (2023), against an average of $3.4 million.
• Across the five-year window, Change in Accured Expenses soared 9304.88% in 2022 and tumbled 1019.19% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at $11.0 million in 2022, then slumped by 31.58% to $7.5 million in 2023, then soared by 55.34% to $11.7 million in 2024, then soared by 120.46% to $25.7 million in 2025, then plunged by 210.33% to -$28.3 million in 2026.
• Per Business Quant, the three latest SNDX Change in Accured Expenses figures stand at -$28.3 million (Q1 2026), $25.7 million (Q4 2025), and $1.1 million (Q3 2025).